Josiah Ayoola Isong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Josiah Ayoola Isong has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Dong-Seong Kim
ICT Convergence Research Center, Department of IT Convergence Engineering, Kumoh National Institute of Technology, Gumi, South Korea
2 shared publications - Simeon Okechukwu Ajakwe
Department of Smart Computing, Kyungdong University
2 shared publications Abdeen Tunde Ogunlana
Computational Biology, Drug Discovery Laboratory, Department of Biochemistry, Ladoke Akintola University of Technology, Ogbomosho, Nigeria
1 shared publicationAbdul-Quddus Kehinde Oyedele
Computational Biology, Drug Discovery Laboratory, Department of Biochemistry, Ladoke Akintola University of Technology, Ogbomosho, Nigeria
1 shared publication- Ibrahim Damilare Boyenle
Computational Biology/Drug Discovery Laboratory, Department of Biochemistry, Ladoke Akintola University of Technology, Ogbomoso, Nigeria
1 shared publication James Babatunde Ayorinde
Department of Biochemistry and Nutrition, Nigerian Institute of Medical Research (NIMR), Lagos, Nigeria
1 shared publication
Latest Publications
- Open Access
- 26 February 2026
- Published by PeerJ in PeerJ Computer Science
- Vol. 12, e3615
ProtChain: a blockchain-enabled framework for secure and reproducible biomedical IoT data workflows
The rapid growth of biomedical Internet of Things (IoT) systems has intensified the challenge of ensuring secure, interoperable, and reproducible data workflows across distributed devices, laboratories, and repositories. Conventional repositories such as the Protein Data Bank (PDB) and UniProt provide standardized data formats, yet they lack scalable mechanisms for real-time synchronization, provenance verification, and trusted sharing in IoT-driven environments. This article presents ProtChain, a blockchain-enabled framework that integrates a permissioned PureChain ledger with decentralized storage (InterPlanetary File System (IPFS)) to deliver secure and high-throughput biomedical workflows. Designed with a microservices architecture, ProtChain enforces Advanced Encryption Standard (AES)-256 encryption, role-based access control, and seamless application programming interface (API) connectivity with bioinformatics repositories. A prototype case study using the HIV-1 protease (1HPV) demonstrates end-to-end ingestion, provenance verification, and retrieval of proteomic data. Performance evaluations show throughput of 485.96 requests per second under 50 concurrent workloads, with blockchain transaction rates reaching 445 transactions per second (TPS) at 10–25 transactions per block, validating scalability for IoT-based biomedical research. By combining blockchain immutability with decentralized storage and standardized APIs, ProtChain addresses pressing challenges of interoperability, data trust, and reproducibility. The results establish ProtChain as a trust backbone for next-generation biomedical IoT ecosystems, enabling secure collaboration, verifiable research pipelines, and scalable healthcare applications.
- 26 February 2026
- Published by PeerJ in PeerJ Computer Science
- Vol. 12, e3615
Open AccessProtChain: a blockchain-enabled framework for secure and reproducible biomedical IoT data workflows
The rapid growth of biomedical Internet of Things (IoT) systems has intensified the challenge of ensuring secure, interoperable, and reproducible data workflows across distributed devices, laboratories, and repositories. Conventional repositories such as the Protein Data Bank (PDB) and UniProt provide standardized data formats, yet they lack scalable mechanisms for real-time synchronization, provenance verification, and trusted sharing in IoT-driven environments. This article presents ProtChain, a blockchain-enabled framework that integrates a permissioned PureChain ledger with decentralized storage (InterPlanetary File System (IPFS)) to deliver secure and high-throughput biomedical workflows. Designed with a microservices architecture, ProtChain enforces Advanced Encryption Standard (AES)-256 encryption, role-based access control, and seamless application programming interface (API) connectivity with bioinformatics repositories. A prototype case study using the HIV-1 protease (1HPV) demonstrates end-to-end ingestion, provenance verification, and retrieval of proteomic data. Performance evaluations show throughput of 485.96 requests per second under 50 concurrent workloads, with blockchain transaction rates reaching 445 transactions per second (TPS) at 10–25 transactions per block, validating scalability for IoT-based biomedical research. By combining blockchain immutability with decentralized storage and standardized APIs, ProtChain addresses pressing challenges of interoperability, data trust, and reproducibility. The results establish ProtChain as a trust backbone for next-generation biomedical IoT ecosystems, enabling secure collaboration, verifiable research pipelines, and scalable healthcare applications.
- Open Access
- 1 January 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Internet of Things Journal
- p. 1
BioPassport: Edge-Attested Biomaterial Provenance for IoT-Integrated Laboratories
- 1 January 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Internet of Things Journal
- p. 1
Open AccessBioPassport: Edge-Attested Biomaterial Provenance for IoT-Integrated Laboratories
- 13 July 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (12) , 5817-5826
Promising disruptors of p53-MDM2 dimerization from some medicinal plant phytochemicals: a molecular modeling study
Cancer is a major global health issue that has a high mortality rate. p53, which functions as a tumor suppressor, is critical in preventing tumor development by regulating the cell cycle and inducing apoptosis in damaged cells. However, the tumor suppressor function of p53 is effectively inhibited by its direct interaction with the hydrophobic cleft of MDM2 protein via multiple mechanisms As a result, restoring p53 activity by blocking the p53-MDM2 protein-protein interaction has been proposed as a compelling therapeutic strategy for cancer treatment. The use of molecular docking and phytochemical screening procedures are appraised to inhibit MDM2's hydrophobic cleft and disrupt the p53-MDM2 interaction. For this purpose, a library of 51 bioactive compounds from 10 medicinal plants was compiled and subjected to structure-based virtual screening. Out of these, only 3 compounds (Atalantoflavone, Cudraxanthone 1, and Ursolic acid) emerged as promising inhibitors of MDM2-p53 based on their binding affinities (-9.1 kcal/mol, −8.8 kcal/mol, and −8.8 kcal/mol respectively) when compared to the standard (-8.8 kcal/mol). Moreover, these compounds showed better pharmacokinetic and drug-like profiling than the standard inhibitor (Chromonotriazolopyrimidine 1). Finally, the 100 ns MD simulation analysis confirmed no significant perturbation in the conformational dynamics of the simulated binary complexes when compared to the standard. In particular, Ursolic acid was found to satisfy the molecular enumeration the most compared to the other inhibitors. Our overall molecular modeling finding shows why these compounds may emerge as potent arsenals for cancer therapeutics. Nonetheless, extensive experimental and clinical research is needed to augment their use in clinics. Communicated by Ramaswamy H. Sarma
- 13 July 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (12) , 5817-5826
Promising disruptors of p53-MDM2 dimerization from some medicinal plant phytochemicals: a molecular modeling study
Cancer is a major global health issue that has a high mortality rate. p53, which functions as a tumor suppressor, is critical in preventing tumor development by regulating the cell cycle and inducing apoptosis in damaged cells. However, the tumor suppressor function of p53 is effectively inhibited by its direct interaction with the hydrophobic cleft of MDM2 protein via multiple mechanisms As a result, restoring p53 activity by blocking the p53-MDM2 protein-protein interaction has been proposed as a compelling therapeutic strategy for cancer treatment. The use of molecular docking and phytochemical screening procedures are appraised to inhibit MDM2's hydrophobic cleft and disrupt the p53-MDM2 interaction. For this purpose, a library of 51 bioactive compounds from 10 medicinal plants was compiled and subjected to structure-based virtual screening. Out of these, only 3 compounds (Atalantoflavone, Cudraxanthone 1, and Ursolic acid) emerged as promising inhibitors of MDM2-p53 based on their binding affinities (-9.1 kcal/mol, −8.8 kcal/mol, and −8.8 kcal/mol respectively) when compared to the standard (-8.8 kcal/mol). Moreover, these compounds showed better pharmacokinetic and drug-like profiling than the standard inhibitor (Chromonotriazolopyrimidine 1). Finally, the 100 ns MD simulation analysis confirmed no significant perturbation in the conformational dynamics of the simulated binary complexes when compared to the standard. In particular, Ursolic acid was found to satisfy the molecular enumeration the most compared to the other inhibitors. Our overall molecular modeling finding shows why these compounds may emerge as potent arsenals for cancer therapeutics. Nonetheless, extensive experimental and clinical research is needed to augment their use in clinics. Communicated by Ramaswamy H. Sarma